Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features

Molecular Psychiatry

Volumn 4, Issue 2, 1999, Pages 182-188

  Anisman, H ^a   Ravindran, A V ^b   Griffiths, J ^b   Merali, Z ^c  

^a CARLETON UNIVERSITY   (Canada)

^b ROYAL OTTAWA HOSPITAL   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

ACTH; Atypical; Cortisol; Cytokine; Depression; Dysthymia; Endocrine; Immune; Interleukin 1; Interleukin 2; Neurovegetative

Indexed keywords

ADRENALIN; CORTICOTROPIN; CYTOKINE; HYDROCORTISONE; INTERLEUKIN 1; INTERLEUKIN 2; NORADRENALIN;

ADRENALIN BLOOD LEVEL; ADULT; ARTICLE; CHRONICITY; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CYTOKINE PRODUCTION; DEPRESSION; DYSTHYMIA; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE SYSTEM; NORADRENALIN BLOOD LEVEL; NORMAL HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0032910530     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000436     Document Type: Article

References (59)

1. Herbert TB, Cohen S. Depression and immunity: a meta-analytic review. Psychol Bull 1993; 113: 472-486.
2. Irwin M. Psychoneuroimmunology of depression. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York, 1995, pp 983-998.
3. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 11-38.
4. Weisse CS. Depression and immunocompetence: a review of the literature. Psychol Bull 1992; 113: 475-486.
5. Maes M, Lambrechts J, Bosmans E, Jacobs J, Suy E, Vandervorst C et al. Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med 1992; 22: 45-53.
6. Maes M, Stevens WJ, Peeters D, DeClerck LS, Bridts CH, Peeters D et al. Significantly increased expression of T-cell activation markers (interleukin-2 and HLA-DR) in depression: further evidence for an inflammatory process during that illness. Prog Psychopharmacol Biol Psychiat 1993; 17: 241-255.
7. Mullar N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiat 1998; 22: 1-33.
8. Calabrese JR, Skwerer RG, Barna B, Gulledge AD, Valenzuela R, Butkus A et al. Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res 1986; 17: 41-47.
9. Dunbar PR, Hill J, Neale TJ, Mellsop GW. Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with schizophrenia. Psychol Med 1992; 22: 1051-1057.
10. Lieb J, Karmali R. Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prost Leukotr Med 1983; 10: 361-368.
11. Maes M, Bosmans E, Suy E, Vandervorst C, DeJonckheere C, Minner B et al. Depression-related disturbances in mitogen-induced lymphocyte responses, interleukin-1β, and soluble interleukin-2-receptor production. Acta Psychiatr Scand 1991; 84: 379-386.
12. Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995; 34: 301-309.
13. Nassberger L, Traskman-Bendz L. Increased soluble interleukin-2 receptor concentrations in suicide attempters. Acta Psychiatr Scand 1993; 88: 48-52.
14. Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann NY Acad Sci 1995: 762: 474-476.
15. Dunn AJ. Interactions between the nervous system and the immune system: implications for psychopharmacology. In: Blomm FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York, 1995, pp 719-731.
16. Rivier C. Effect of peripheral and central cytokines on the hypothalamic-pituitary-adrenal axis of the rat. Ann NY Acad Sci 1993; 697: 97-105.
17. Irwin M, Mascovich A, Gillin JC, Willoughby R, Pike J, Smith TL. Partial sleep deprivation reduces natural killer cell activity in humans. Psychosom Med 1994; 56: 493-498.
18. Moldofsky H. Sleep and the immune system. Int J Immunopharmacol 1995; 17: 649-654.
19. Kiecolt-Glaser JK, Glaser R. Psychosocial factors, stress, disease and immunity. In: Ader R, Felten DL, Cohen N (eds). Psychoneuroimmunology. Press: New York, 1991, pp 847-867.
20. Asnis GM, McGinn LK, Sanderson WC. Atypical depression: clinical aspects and noradrenergic function. Am J Psychiatry 1995; 152:31-36.
21. Quitkin FM, Harrison WM, Stewart JW, McGrath PJ, Tricamo E, Ocepek-Welikson K et al. Response to phenelzine and imipramine in placebo responders with atypical depression. Arch Gen Psychiatry 1991; 48: 319-323.
22. Stewart JW, McGrath PJ, Rabkin JG, Quikin FM. Atypical depression: a valid clinical entity? Psychiatr Clin N Am 1993; 16: 479-495.
23. Derecho CN, Wetzler S, McGinn LK, Sanderson WC, Asnis GM. Atypical depression among psychiatric inpatients: clinical features and personality traits. J Affect Disord 1996; 39: 55-59.
24. Nemeroff CB. The coricotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry 1996; 1: 336-342.
25. McGinn LK, Asnis GM, Rubinson E. Biological and clinical validation of atypical depression. Psychiatry Res 1996; 60: 191-198.
26. Quitkin FM, Stewart JW, McGrath PJ, Liebowitz MR, Harrison WM, Tricamo E et al. Phenelzine vs imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1998; 145: 306-311.
27. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Rabkin JJ et al. Phenelzine vs imipramine in atypical depression: a preliminary report. Arch Gen Psychiatry 1984; 41: 669-677.
28. McGrath PJ, Stewart JW, Harrison WM, Ocepek-Wilekson K, Rabkin JG, Nunes EN et al. Predictive value of symptoms of atypical depression for differential drug treatment outcome. J Clin Psychopharmacol 1992; 12: 197-202.
29. Thase ME, Carpenter L, Kupfer DJ, Frank E. Clinical significance of reversed neurovegetative subtypes of recurrent major depression. Psychopharmacol Bull 1991; 27: 17-22.
30. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res 1986; 17: 87-95.
31. Akiskal HS. Dysthymic disorder: psychopathology of proposed chronic depressive subtypes. Am J Psychiatry 1983; 140: 11-20.
32. Akiskal HS, Weise RE. The clinical spectrum of so-called 'minor' depressions. Am J Psychotherapy 1992; 46: 9-22.
33. Thase ME, Howland RH. Biological processes in depression: an updated review and integration. In: Reckham EE, Leber WR (eds). Handbook of Depression. Guilford Press: New York, 1995.
34. Ravindran AV, Merali Z, Anisman H. Dysthymia: a biological perspective. In: Licinio J, Bolis CL, Gold P (eds). Dysthymia: From Clinical Neuroscience to Treatment. World Health Organization: Geneva, 1997, pp 21-44.
35. Plotsky PM, Owens MJ, Nemeroff CB. Neuropeptide alterations in mood disorders. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York, 1995, pp 971-981.
36. Holsboer F. Neuroendocrinology of mood disorders. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York, 1995, pp 957-969.
37. Gold PW, Licinio J, Wong ML, Chrousos GP. Corticotropin releasing hormone in pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann NY Acad Sci 1995; 771: 716-729.
38. Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJP et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991; 148: 337-344.
39. Levitan RD, Kaplan AS, Brown GM, Joffe RT, Levitt AJ, Vaccarino FJ et al. Low plasma cortisol in bulimia nervosa patients with reversed neurovegetative symptoms of depression. Biol Psychiatry 1997; 41: 366-368.
40. Joseph-Vanderpool JR, Rosenthal NE, Chrousos GP, Wehr TA, Skwerer R, Kasper S et al. Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder: clinical and pathophysiological implications. J Clin Endocrinol Metab 1991; 72: 1382-1387.
41. Akil HA, Morano MI. Stress. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York, 1995, pp 773-785.
42. De Groote D, Gevaert Y, Lopez M, Gathy R, Fauchet F, Dehart I et al. Novel method for the measurement of cytokine production by a one-stage procedure. J Immunol Meth 1993; 163: 259-267.
43. Maes M, Meltzer HY, Stevens W, Cosyns P, Blockx P. Multiple reciprocal relationships between in vivo cellular immunity and hypothalamic-pituitary-adrenal axis in depression. Psychol Med 1994; 24: 167-177.
44. Benschop RJ, Nieuwenhuis EES, Tromp EAM, Godaert GLR, Ballieux RE, van Doornen LJP. Effects of β-adrenergic blockade on immunologic and cardiovascular changes induced by mental stress. Circulation 1994; 89: 762-769.
45. Ravindran AV, Griffiths J, Merali Z, Anisman H. Circulating lymphocyte subsets in major depression and dysthymia with typical or atypical features. Psychosom Med 1998; 60: 283-289.
46. Maes M, Meltzer H, Cosyns P, Calabrese J, D'Hondt P, Blockx P. Adrenocorticotropic hormone, β-endorphin and cortisol responses to oCRH in unipolar depressed patients pretreated with dexamethasone. Prog Neuro-Psychopharmacol Biol Psychiatry 1994; 18: 1273-1292.
47. Szadoczky E, Sazekas I, Rihmer Z, Arato M. The role of psychosocial and biological variables in seperating chronic and non-chronic major depression and early-late onset dysthymia. J Affect Disord 1994; 32: 1-11.
48. Akiskal HS, Bolis CL, Cazzullo C, Costa e Silva JA, Gentil V, Lecrubier Y et al. Dysthymia in neurological disorders. Mol Psychiatry 1996; 1: 478-491.
49. Tilders FJH, Schmidt ED, De Goeij DCE. Phenotypic plasticity of CRF neurons during stress. Ann NY Acad Sci 1993; 697: 39-52.
50. Gold PW, Chrousos GP, Kellner C, Post RM, Roy A, Augerinas P et al. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am J Psychiatry 1984; 141: 619-627.
51. Munck A, Guyre PM. Glucocorticoids and immune function. In: Ader R, Felten DL, Cohen N (eds). Psychoneuroimmunology. Academic Press: New York, 1991, pp 447-462.
52. Griffiths J, Ravindran AV, Merali Z, Anisman H. Immune and behavioral correlates of typical and atypical depression. Soc Neurosci Abs 1996; 22: 1350.
53. Kent S, Bluthe RM, Kelley KW, Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992; 13: 24-28.
54. Baroja ML, Cueppens JL. More exact quantification of interleukin-2 production by addition of anti-Tac monoclonal antibody to cultures of stimulated lymphocytes. J Immunol Meth 1987; 98: 267-270.
55. Akiskal HS. Towards a definition of dysthymia: boundaries with personality and mood disorders. In: Burton SW, Akiskal HS (eds), Dysthymic Disorder. Gaskell: London, 1990, pp 1-12.
56. Sheehan D, Lecrubier Y, Janavs J, Knapp E, Weiller E, Sheehan M et al. Mini-international Neuropsychiatric Interview, Clinician Rated, version 2.1, 1992.
57. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-569.
58. Seegal RF, Brosch KO, Bush B. High-performance liquid chromatography of biogenic amines and metabolites in brain, cerebrospinal fluid, urine and plasma. J Chromatog 1986; 377: 141-144.
59. Ravindran AV, Griffiths J, Merali Z, Anisman H. Primary dysthymia: a study of several psychosocial, endocrine and immune correlates. J Affect Dis 1996; 40: 73-84.